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Regulatory and HTA documents were analyzed to identify the processes of appraisal, 
indications assessed and key factors driving agency decisions. Results: Overall, 
twenty-one indications were appraised for the four biosimilars collectively; 90% of 
appraisals produced a decision of ‘recommended’, 9% were ‘recommended with 
restrictions’, and 1% were ‘not recommended’. Demonstration of clinical compa-
rability between the biosimilar and the reference product was a requirement in 
all countries. Cost-minimization and budget impact analyses were key economic 
decision factors. Some agencies accepted the notion of comparability for extrapola-
tion to indications other than those that had been studied in clinical trials. Pricing 
dynamics were seen to differ between biosimilars, driven by a combination of pric-
ing strategies for reference biologics, and payer and physician reservations about 
potential risks. ConClusions: Regulatory bodies follow common principles of 
assessment but differences exist with respect to scope and choice of reference prod-
uct. Important factors common to reimbursement agencies included comparable 
efficacy and safety of biosimilars to the reference products, and economic consid-
erations; however, they differed in their appraisal processes. The relative weight of 
price versus potential risk may vary with the disease area targeted by the biologic. 
The currently approved biosimilars have been relatively simple biologics to re-create 
and therefore evaluate, but the experience gained should be built upon to address 
the challenges of assessing the increasingly complex biosimilars being developed.
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objeCtives: This paper empirically investigates the role of patient-physician 
communication on the likelihood of receiving appropriate care, and its effect on 
health care costs at hospital inpatient settings. Methods: The Healthcare Cost and 
Utilization Project (HCUP) 2008-2010 State Inpatient Databases (SID) for Florida were 
used in this analysis. Then, we linked Florida SID with Florida Physician Licensure, 
the American Hospital Association Annual Survey Database; and the Area Resource 
File. Our key covariate of interest is the association between Spanish speaking phy-
sicians and Hispanic patients with the total costs associated with that visit. We 
started with descriptive analysis. Next, we used logistic regression models to assess 
likelihood of choosing a Spanish speaking physician over other physicians. Next, 
we used generalized linear regression models to estimate and then compare the 
health care costs associated Hispanic patients with Spanish speaking physicians 
against others. We also used Oaxaca-Blinder (OB) Decomposition to compare the 
health care costs between and within Hispanic and non-Hispanic white patients 
across Spanish and non-Spanish speaking physicians. To assess the robustness of 
our baseline results, we conducted several empirical estimations and tested their 
significance. Results: Our risk adjusted estimates show that the odds ratios for 
Hispanic patients registered to Spanish speaking physicians is 3.8 compared to 
non-Hispanic white patients registered to Spanish speaking physicians. We found 
that hospital inpatient costs associated with Hispanic patients registered to Spanish 
speaking physicians is about $650 less relative to Hispanic patients registered to 
non-Spanish speaking physicians. Our risk-adjusted results also show that hospi-
tal inpatient costs associated with non-Hispanic white patients registered to non-
Spanish speaking physicians relative to the non-Hispanic white patients registered 
to Spanish speaking physicians are lower by about $700 per visit. ConClusions: 
We found a strong correlation between Hispanic patients and Spanish speaking 
physicians. Better communications between patients and providers can provide 
patients with better care.
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objeCtives: The primary objective of this study is to examine the hospitals’ risk-
adjusted costs, and Medicare Advantage (MA) enrollees and Fee-for-service (FFS) 
beneficiaries’ use of high-cost hospitals. The second objective of this study is to 
document the variation in racial and ethnic disparity in visiting high-cost hospitals 
within and between MA enrollees and FFS beneficiaries as policymakers mostly have 
focused on the location of care as an explanation for important disparities in many 
health outcomes. Methods: We used 2006-2010 Healthcare Cost and Utilization 
Project State Inpatient Databases from California, Florida, Massachusetts, New York, 
Tennessee and Wisconsin; American Hospital Association Annual Survey Database; 
and Area Resource Files. We calculated the hospital cost index by dividing the actual 
total costs by casemix adjusted total costs. Next, we calculated three categorical 
values to define the dependent variable for each state, which takes value 1 if the 
hospital cost-index is less than 0.95; value 2 if it is within 0.95 -1.05; and, value 3 if it 
is greater than 1.05. We used ordered logistic regression models. We also estimated 
the same model using a different specification of high-cost hospital definitions to 
ascertain any effects resulting from sample sizes. Results: We found lower preva-
lence of high-cost hospitals among MA enrollees than among FFS beneficiaries. Our 
risk adjusted results show that the odds ratios of visiting a high-cost hospital for MA 
enrollees range from 0.641 to 0.958 for all states. Our results show that non-white 
elderly patients associated with lower likelihood of visiting high-cost hospitals in 
in California and New York, and higher likelihood of visiting high-cost hospitals in 
Florida, Massachusetts, Tennessee and Wisconsin. ConClusions: MA enrollees 
mostly utilize low-cost hospitals for their health care needs. We find sizable geo-
graphic variation in visiting high-cost hospitals among minority elderly population.
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life insurances, ranking #1 worldwide in 2012. For individuals who purchase private 
insurances to add protections it is natural to ask which insurance policy provides the 
most favorable return. The objective of this study is to establish a valuation system 
for private life and annuity insurance plans using a robust, flexible, distributed 
cloud computing architecture. Methods: Using the fixed income model and by 
constructing polynomial interpolated yield curves from Taiwan government and 
corporate bonds, we can approximate the internal rate of returns of each insur-
ance policy and compare their performance versus the time value of money of 
the total investments. We extracted daily information from over-the-counter mar-
kets and Taiwan interbank interest rates to compute daily changes in policy val-
ues. Results: Shown in our experiments, by investing in insurance policies from 
30 to 85 years old, the policies provide -0.1% to -1.4% returns, which represents the 
total value of investments has diminished throughout the years. Even in the event 
of benefit claims (severe injury or death), the insurances provides -0.2% to 1.5% 
returns. For annuity insurances, early investments do not provide advantages, i.e., 
by investing at 30 and by 50 years old, the returns is approximately the same at 85 
years old. ConClusions: We establish a robust, flexible and efficient valuation 
system for private life and annuity insurance plans. Results show that even by 
purchasing private insurances, the extra protections provided is still inadequate to 
cover major emergency medical conditions.
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objeCtives: The objective of this study is to estimate the effects of the 
Massachusetts health care reform on the use of inpatient hospital services in 
Massachusetts. Methods: We used Healthcare Cost and Utilization Project State 
Inpatient Databases for the years 2004-2011 in 37 states including Massachusetts. 
We identified a control group of hospitals from other states for each year based on 
their characteristics that match the hospitals in Massachusetts. Hospital-specific 
utilization was summarized by calendar quarter, and difference-in-differences time 
series models were estimated based on the multi-year implementation of reform 
initiatives in Massachusetts. We identified a pre-reform period (Q1 2004-Q3 2006), 
during period (Q4 2006-Q2 2007), and two post-reform periods (Q3 2007-Q1 2009 and 
Q2 2009-Q4 2011). Dependent variables were the quarterly estimate for each hospital 
of the natural logarithm of total discharges, average length of stay, the coefficient of 
variation in length of stay, and cost per discharge. Independent variables included 
annual measures of the Herfindahl-Hirschman Index, county-level measures of popu-
lation, household income, unemployment rate, labor force participation rate and a 
dichotomous variable indicating if the hospital was in Massachusetts and the stage of 
policy implementation in the state. The regression models also controlled for the dif-
ferential effects of the dramatic changes that occurred across the country. Results: 
Our descriptive results indicate that the number of discharges grew more rapidly in 
Massachusetts than in the rest of the country. Our risk adjusted results show that 
the full implementation of the reform legislation led to 5.8% more discharges, 5.0% 
shorter lengths of stay, a 2.5% reduction in the variation in a hospital’s length of stay 
and no change in cost per discharge – all relative to control hospitals. ConClusions: 
Massachusetts health care reform had a modest impact on inpatient utilization and 
that impact became greater the longer the reform was in place.
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objeCtives: Cost effectiveness analyses are required by various Health Technology 
Assessment (HTA) agencies as part of the reimbursement submission. To gain an 
insight into the methods used, we analyzed the cost effectiveness studies for the 
top twenty highest selling drugs (~$90-100B worldwide sales). Methods: The Top 20 
drugs were selected based on their worldwide sales. For this analysis, we segmented 
these drugs into categories such as primary care, specialty, small molecules, bio-
logics, therapy areas, and availability of generic alternatives. We analyzed the cost 
effectiveness studies that were published in peer-reviewed journals. Searches were 
conducted using generic names of the drugs and the phrase “cost effectiveness” in 
an abstract of the published study. Results: Between 2008-2013, the number of 
published studies on “cost effectiveness” has increased by more than 35%. There 
is a large variability in CERs for same drugs for different indications, in some cases 
also varying by biomarkers. Primary care drugs had lower and less variable CERs 
than specialty drugs. Variations also exist in methodology used by different groups 
in modeling cost effectiveness, especially for time horizon and comparator. The 
majority of primary care drugs were modeled for a time horizon of 35-40 years or for 
a lifetime to demonstrate cost effectiveness. ConClusions: This analysis shows 
the range, variability, and methods used for calculation of ICER values for these 
high budget impact drugs and provides lessons for executives and policy makers.
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objeCtives: Biosimilars are biotherapeutic products that are similar in terms of 
quality, safety and efficacy to an already licensed reference biologic. There are strict 
guidelines in place for the regulatory approval of biosimilars. However, HTA agen-
cies differ in their approaches to appraisal of biosimilars. This study examined 
the factors influencing regulatory and reimbursement decisions for biosimilars in 
different countries. Methods: A qualitative documentary analysis was performed 
of the regulatory approval and reimbursement of four biosimilars in nine countries. 
